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Background: Proximal aortic dilatation in certain congenital heart diseases (CHD) prompts concerns about
dissection and consideration of prophylactic surgery. To evaluate contemporary prophylactic practice, we deter-
mined incidence of aortic dissection andprophylactic surgery in aortopathy-associatedCHD, compared toMarfan
syndrom (MFS) and controls.
Methods and results: We followed patients from the CONCOR adult CHD registry (2002–2015), with a native
proximal aorta and aortopathy-associated CHD, comprising bicuspid aortic valve/aortic stenosis (‘BAV/AS’;
n = 2239) and aortic coarctation/conotruncal defects/univentricular heart/ventricular septal defect (‘At-risk
CHD’; n=5439). As reference,we selectedMFS (n=356) and ‘Control’ (atrial septal defect, pulmonary stenosis;
n = 2940) patients. Cumulative incidences of dissection and prophylactic proximal aortic replacement –
considered competing events – were determined, and compared corrected for age and sex. Median follow-up
was 6.7 years. Ten-year dissection-incidence was 0.3% (95%CI: 0.0–0.7) in BAV/AS and 0.2% (0.0–0.3) in At-risk
CHD, both significantly lower than in MFS (4.1%; 1.8–6.4) and similar to Controls (0.1%; 0.0–0.3). Ten-year
prophylactic-surgery incidence was 9.3% (7.6–11.0) in BAV/AS and 0.7% (0.5–1.0) in At-risk CHD, both signifi-
cantly lower than in MFS (21.3%; 16.3–26.3) and higher than in Controls (0.1%; 0.0–0.3).
Conclusions: In contemporary practice, aortic-dissection incidence is low in adults with aortopathy-associated
CHDs, while prophylactic-surgery incidence is high in BAV/AS. To reduce surgical burden, BAV/AS patients
could benefit from more individualised prophylactic-surgery algorithms.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Proximal aortic dilatation is common in certain congenital heart
diseases (CHD), prompting concerns about aortic dissection and
consideration of prophylactic aortic replacement [1–3]. Guideline-
recommendations for prophylactic surgery are subject to ongoing de-
bate for bicuspid aortic valve (BAV) and lacking for other CHD types
[1,4,5]. To evaluate contemporary practice, we determined incidence of
aortic dissection (AD) andprophylactic proximal (root/ascending) aortic
replacement surgery (PPAR) in patients with aortopathy-associated
CHD with a native proximal aorta, compared to Marfan syndrome
(MFS) and controls.
2. Methods
2.1. Study population and data collection
The cohort comprised ≥18-year-old patients from theCONCORDutch adult CHD registry.
The study conforms to the Declaration of Helsinki, andwas approved by the ethics boards of
all participating centers [6]. Since 2002, after written informed consent, baseline and follow-
up clinical events are obtained from medical records. In patients with multiple CHDs, the
most severe according to a consensus-based classification is designated the primary CHD [7].
We selected patients with a native proximal aorta (or neo-aorta after arterial
switch) at inclusion, and a primary diagnosis of aortopathy-associated CHD, com-
prising (1) BAV (n = 1815) or aortic stenosis (AS; n = 424) (‘BAV/AS’; n =
2239), and (2) ‘At-risk CHD’ (n = 5439), comprising aortic coarctation (CoA, n =
734), conotruncal defects (n = 2142; tetralogy of Fallot, transposition complex,
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pulmonary atresia, double-outlet right ventricle), univentricular heart (n = 270)
and ventricular septal defect (VSD; n = 2293). As reference, we selected patients
with MFS (n = 356) and ‘Controls’ with non-aortopathy-associated CHD (atrial sep-
tal defect or pulmonary stenosis; n = 2940). Subjects with BAV and CoA are included
as BAV/AS, those with another primary CHD and BAV as a secondary diagnosis were
excluded.
Patients were followed for AD and PPAR (not preceded by dissection/rupture;
definition: Supplemental Table I). Follow up started 3 months after CONCOR in-
clusion, to correct for possible inclusion conditional on instantaneous risk (e.g.
during (pre)operative hospital admission). Follow-up ended at the outcome, latest
medical record review, death or end-of-study (October 10th 2015), whichever oc-
curred first.
Medical/imaging records of 91/130 PPARs in BAV/AS and 24/34 in At-risk CHD pa-
tients from high-volume centers were retrospectively reviewed for surgical indications
(retrieved: 89 BAV/AS, 24 At-risk CHD) and largest pre-operative aortic diameter
(retrieved: 78 BAV/AS, 23 At-risk CHD).
2.2. Statistical analysis
Cumulative incidence function curves were constructed, including AD, PPAR and death
as competing events, and compared using Gray's test. Proportional subdistribution hazards
regression was performed, correcting for age and sex (additionally correcting for baseline
aortic valve replacement [AVR] only marginally affected results) [8]. Additional pairwise
analyses were performed. AD fatality, and mortality b3 months after PPAR was assessed
and compared between groups. Results from regression analyses are reported as
subdistribution hazard ratios (sdHRs) with 95% confidence intervals (CIs) and p-values.
Testswere two-sided (alpha: 0.05, Bonferroni correction formultiple comparisons). Analyses
were performed using R version 3.2.4 (R Foundation, Vienna, Austria) and SPSS version 23
(IBM Corp., Armonk, NY, USA).
3. Results
3.1. Baseline characteristics
Baseline characteristics are presented in Table 1. BAV/AS patients
were older, and had proportionately more males and baseline AVR
than the others. MFS and At-risk CHD were relatively more often
followed in tertiary centers.
3.2. Aortic dissection and prophylactic surgery
Table 1 shows the number of incident ADs and PPARs, age at occur-
rence and mortality. Fig. 1 shows cumulative AD (A) and PPAR (B) inci-
dence, with results from multivariable regression analyses.
Ten-year cumulative AD incidence was 0.3% (95%CI: 0.0–0.7) in
BAV/AS, 0.2%, (0.0–0.3) in At-risk CHD, 4.1% (1.8–6.4) in MFS and 0.1%
(0.0–0.3) in Controls (p b 0.001 across groups). Multivariable analyses
showed AD risk was significantly higher than in Controls only in MFS
(Fig. 1A). Risk was higher in MFS than in both BAV/AS (sdHR =
13.2; 95%CI: 4.2–41.2, p b 0.001) and At-risk CHD (sdHR = 24.2;
9.2–63.8, p b 0.001), and not different in BAV/AS versus At-risk CHD
(sdHR= 1.5; 0.4–5.7, p= 0.570). Age at ADwas relatively high in Con-
trols, AD fatality relatively low in MFS patients (Table 1, Supplemental
Table II).
Ten-year cumulative PPAR incidencewas 9.3% (7.6–11.0) in BAV/AS,
0.7% (0.5–1.0) in At-risk CHD, 21.3% (16.3–26.3) in MFS and 0.1%
(0.0–0.3) in Controls (p b 0.001 across groups). Multivariable analyses
showed significantly higher PPAR incidence compared with Controls
in all other groups (Fig. 1B). Risk was higher in MFS than in both BAV/
AS (sdHR = 2.6; 1.9–3.6, p b 0.001) and At-risk CHD (sdHR = 30.6;
19.9–47.1, p b 0.001), and higher in BAV/AS than in At-risk CHD
(sdHR = 10.2; 6.9–15.1, p b 0.001). Table 1 shows concomitant AVR
was more frequent in BAV/AS and At-risk CHD than in MFS. Age at
PPAR was similar between groups, and between PPAR with/without
AVR (overall and within groups). Three-month PPAR mortality was
not significantly different between groups (Table 1).
Supplemental Tables IIIa and IIIb show data concerning indications
for PPAR and maximum pre-operative proximal aortic diameters,
respectively. All stand-alone PPARs were indicated for aortic dilatation,
alone or with aortic insufficiency. For PPAR with AVR, dilatation was
the only indication reported in 20% of BAV/AS and 53% of At-risk-CHD
cases; the rest included valve dysfunction (p = 0.020). In BAV, mean
pre-operative aortic diameter was lower with concomitant AVR
(45.1[standard deviation = 7.3]mm, without: 50.0[4.1]mm, p b 0.001),
Table 1
Baseline characteristics and outcome data per group.
BAV/AS At-risk CHD MFS Control p-Valuea
Baseline characteristics
N 2239 5439 356 2940
Age, years 35.0 (23.4–48.6) 29.7 (21.6–42.3) 33.8 (24.4–45.6) 39.7 (26.6–54.4) b0.001†
Male 1449 (64.7) 2762 (50.8) 157 (44.1) 1041 (35.4) b0.001‡
AVR 373 (16.7) 93 (1.7) 1 (0.3) 14 (0.5) b0.001§
Tertiary center 1427 (63.7) 3894 (71.6) 320 (89.9) 1641 (55.8) b0.001||
Follow up time, years
Median 6.0 (2.8–9.4) 7.1 (3.6–10.3) 9.3 (5.8–11.3) 6.1 (3.0–9.1) b0.001¶
Total 13,959 37,752 2970 17,872
ADs in follow up
n 4 (0.2) 6 (0.1) 12 (3.4) 2 (0.1)
Male 2 (50.0) 4 (66.7) 3 (25.0) 2 (100)
Age at AD, years 44.3 (34.4–75.1) 48.8 (32.4–69.6) 44.1 (31.2–54.5) 67.7 (64.2-…) 0.506#
Fatal AD 3 (75.0) 4 (66.7) 2 (16.7) 2 (100) 0.024#
PPARs in follow up
n 130 (5.8) 34 (0.6) 63 (17.7) 1 (0.0)
Male 90 (69.2) 25 (73.5) 38 (60.3) 1 (100)
Concomitant AVR 98 (75.4) 25 (73.5) 19 (30.2) 0 (0.0) b0.001⁎⁎
Age at PPAR, years 40.7 (29.5–50.4) 37.4 (29.6–47.4) 36.1 (26.6–46.0) 36.2 0.123#
Died b3 months after PPAR 2 (1.5) 2 (5.9) 0 (0.0) 0 (0.0) 0.141#
Categorical variables are summarized as number (%), and compared using theχ2 or Fisher's exact test. Continuous variables are summarized asmedian (interquartile range), and compared
using the Kruskal Wallis or Mann-Whitney U test.
Abbreviations: AS, aortic stenosis; AVR, aortic valve replacement; BAV, bicuspid aortic valve; CHD, congenital heart disease; MFS, Marfan syndrome.
a Overall across-group comparison.
† BAV/AS vs MFS: p = NS. All other pairwise: p b 0.008.
‡ At-risk CHD vs MFS: p = NS. All other pairwise: p b 0.008.
§ At-risk CHD and Control vs MFS, p = NS. All other pairwise: p b 0.008.
|| All pairwise comparisons: p b 0.008.
¶ BAV/AS vs Control: p = NS. All other pairwise: p b 0.008.
# All pairwise: p = NS.
⁎⁎ BAV/AS and At-risk CHD vs MFS: p b 0.008. All other pairwise: p = NS.
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and if the indication for surgery included valve dysfunction (43.0[6.3]
mm, no valve dysfunction: 52.0[3.5]mm, p b 0.001). In At-risk CHD, it
differed by indication (included valve dysfunction: 44.9[3.2]mm, no
valve dysfunction: 54.1[5.6]mm, p b 0.001), not by concomitant AVR.
In BAV/AS, mean diameter was similar between periods of different
guideline-recommended diameter-thresholds for PPAR, and there was
no correlation between calendar-time and pre-operative diameters
(overall, and stratified by AVR and indication).
Aortic-dissection incidence was not different between patients with
BAV with and without CoA, PPAR incidence was significantly higher in
the latter (Supplemental Fig. I).
4. Discussion
This study reassuringly shows low aortic-dissection risk in patients
with aortopathy-associated CHD types and a native proximal aorta in
contemporary practice: similar to controls and much lower than in
MFS. Incidence of prophylactic aortic replacement was high in BAV/AS,
but not in other aortopathy-associated CHD.
Low aortic-dissection risk in BAV/AS agrees with observations in
population-based [1,9] and post-AVR [10] BAV cohorts. The latter also
found ~12× lower risk compared toMFS [10]. Present aortic-surgery in-
cidencewas comparably high. This is likely due to proportionatelymore
valve dysfunction requiring AVR, a predictor for aortic surgery [9], in our
clinical cohort with predominantly native valves. For other aortopathy-
associated CHD, low dissection risk in is in line with sporadically
reported dissections in these patients, while data on aortic-surgery inci-
dence is lacking [1].
During the study-period (2002–2015), guideline-recommended
aortic-diameter thresholds for prophylactic surgery in BAV ranged
from conservative (55 mm) in 2002, via aggressive (40 mm) in 2010,
back to currently conservative (55 mm, or 50 mmwith risk-factors). It
ranged between 40 and 50 mm (currently 45 mm) at the time of AVR
for dysfunctional BAV [2,3,5]. No specific guidelines for aortic dilatation
in other aortopathy-associated CHDs exist [1,2].While the observational
nature of this study precludes conclusions concerning its efficacy, pres-
ent results reflect clinical practice over the study period.
Regarding BAV/AS, low dissection- and high prophylactic-surgery
incidence may either indicate effective contemporary prophylactic
practicewith justifiably high surgical burden, or substantiate the notion
that aggressive guidelines induce unnecessary prophylactic operations,
possibly worsening overall outcome [5]. Importantly, many prophylac-
tic aortic replacements were performedwith AVR for valve dysfunction,
often at moderate dilatation in reviewed cases. However, observational
data in BAV patients with moderately dilated aortas showed no long-
term difference in dissections or repeat operations compared with
isolated AVR [11], while concurrent aortic replacement may increase
operative risk [12]. Maximum pre-operative aortic diameters in the
present study suggest rather aggressive prophylactic practice, constant
over the study-period despite changing guidelines. This may reflect
influence of operator and/or patient preference on timing of surgery
[4]. Importantly, guidelines are based on nonrandomized data and ex-
pert consensus. Moreover, aortic diameter is an imperfect marker for
dissection-risk [13], while hemodynamic and genetic factors probably
contribute in the heterogeneous BAV-associated aortopathy [4].
Of note, European guidelines consider CoA a risk factor for dissection
in BAV patients, eliciting surgery at the reduced (50 mm) threshold
[2]. However, we found CoA associated with similar dissection risk,
despite lower prophylactic-surgery incidence, in BAV patients. System-
atic data and reliable markers for dissection-risk are necessary to pro-
vide targeted prophylactic algorithms with a strong evidence-base,
and thus improve uniform clinical practice and ultimately reduce surgi-
cal burden [4].
Regarding aortopathy-associated CHDother than BAV/AS, dissection-
risk was low without frequent surgery. While a restrictive policy fol-
lowing general aortic-disease guidelines (55 mm) seems appropriate
in these patients, aortic surgery was sometimes performed at lower
aortic diameters, particularly if surgery was indicated for aortic valve
dysfunction [1–3].
This study is limited by its observational nature. Known risk-factors
for, and determinants of dissection and treatment decisions were
unavailable. Locations (proximal/distal) of dissections, important re-
garding the rationale of prophylactic proximal aortic surgery, were not
recorded. Surgical indications and pre-operative diameters were retro-
spectively collected for a proportion of cases. Our clinical cohort from
secondary/tertiary centers likely represents a selection with more
severe/overt disease from the CHD-population, particularly for BAV,
which may remain asymptomatic well into adulthood. Longer follow
up inMFS andAt-risk CHD reflects CONCOR inclusion starting in tertiary
centers, thus including patients with more severe CHD earlier [14].
In conclusion, the present study confirms contemporary aortic risk
in aortopathy-associated CHD is much lower than in MFS. As incidence
of prophylactic surgery is high in BAV/AS, research should focus on
identifying patients at highest risk, to target surgery and reduce surgical
burden in BAV/AS patients. A restrictive approach seems appropriate in
other aortopathy-associated CHD-types.
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Fig. 1. Cumulative incidence of aortic dissection (A) and prophylactic proximal aortic replacement (B) per group. * Results frommultivariable subdistribution hazards regression analysis,
including diagnostic group as a categorical variable, correcting for age and sex. Presented as sdHR (95% confidence interval) and p-values. Abbreviations: AS, aortic stenosis; BAV, bicuspid
aortic valve; CHD, congenital heart disease; MFS, Marfan syndrome; sdHR, subdistribution hazard ratio.
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